Phase II, Open Label, Single Arm Study to Investigate Anti-tumor Effect of Ixabepilone in Patients With Locally Recurrent or Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP After Failure of an Anthracycline and Taxanes.

The purpose is to investigate anti-tumor effect of ixabepilone in patients with locally recurrent or metastatic breast cancer (mBC) selected by the Ixabepilone DRP after failure of an anthracycline and taxanes.

Start Date01 Mar 2021

Sponsor / Collaborator

Allarity Therapeutics, Inc.

NCT03925233

/ Unknown statusNot ApplicableIIT

Sensitivity Detection and Drug Resistance Mechanism of Breast Cancer Therapeutic Drugs Based on Organ-like Culture

Based on the breast cancer organ platform, this experiment establishes a drug sensitivity test method that is closer to the body tumor in breast cancer, provides a basis for the accurate treatment of breast cancer, and discusses the possible mechanism of breast cancer drug resistance.

Start Date02 Jan 2019

Sponsor / Collaborator

Xijing Hospital

NCT03393741

/ TerminatedNot ApplicableIIT

Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

Eligible subjects will be assigned to study treatment arms by their treating oncologist, rather than by the study. The drug, dose, and schedule of administration will be determined by the treating physician per NCCN guidelines for standard of care chemotherapy regimens for recurrent or metastatic breast cancer. Study treatment arms include: Taxane (nab-paclitaxel or paclitaxel), Eribulin, Vinorelbine, Ixabepilone, or the control arm (non-microtubule targeted chemotherapies such as doxorubicin, carboplatin, or gemcitabine).

Start Date29 Jan 2018

Sponsor / Collaborator

University of Wisconsin-Madison

[+1]

100 Clinical Results associated with Ixabepilone

100 Translational Medicine associated with Ixabepilone

100 Patents (Medical) associated with Ixabepilone

517

Literatures (Medical) associated with Ixabepilone

01 Sep 2025·FOOD CHEMISTRY

The aroma evolution in lotus (Nelumbo nucifera Gaertn.) seed juice: A comprehensive analysis of processing and low-temperature storage effects

Article

Author: Jiang, Xiangfu ; Lu, Xu ; Zhou, Taoyi ; Mao, Sirui ; Lei, Qiuming ; Zheng, Baodong ; Huang, Zhanhong ; Zhou, Fuzhen ; Ma, Shuang

Lotus seed juice has significant potential in the plant-based beverage market owing to its distinctive flavor. However, its sensory quality is significantly influenced by processing and storage conditions. This study examined the effects and underlying mechanisms of fresh squeezing, sterilization, and refrigeration at 4 °C (for 1-6 months) on the aroma profile of lotus seed juice using an electronic nose, gas chromatography-ion mobility spectrometry (GC-IMS), and non-targeted metabolomics. Sterilization processes resulted in vanilla, mint, and ammonia-like flavors due to the accumulation of hexanal, pentanal, and pyrrolidine. One month of refrigeration enhanced fruity and minty flavors, attributed to increased acetone and 6-ethyl acetate-D from fatty acid oxidation and esterification, respectively. However, prolonged refrigeration (six months) introduced undesirable alcoholic and pungent off-flavors caused by slow oxidative degradation (such as 2-propanol and 1-hydroxy-2-propanone). These findings provide valuable insights for improving the preservation methods and quality control strategies for plant-based beverages.

15 Jul 2025·ACS Omega

Integrating Multiomics and Machine Learning: Senescence-Regulated ALMS1-IT1/miR-7c-5p/HMGA2 Axis as a Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma

Article

Author: Zhu, Yongwu ; Qiu, Tao ; Peng, Lianjie ; Yang, Zhan ; Qin, Luying ; Zhu, Jiani ; Wang, Yuxuan ; Xi, Ziyu ; Luo, Yaxian ; Sun, Mouyuan ; Ying, Kai ; Wang, Fan ; Ma, Yixuan

Head and neck squamous cell carcinoma (HNSCC) is distinguished by the absence of definitive diagnostic markers and effective treatment modalities, which results in its poor clinical outcomes. Although senescence-targeted therapies have emerged as promising interventions, the functional complexity of cellular senescence in HNSCC pathogenesis remains poorly characterized. This study investigated the role of senescence levels in HNSCC through an extensive multiomics analysis coupled with a diverse array of machine learning algorithms. Results indicate that elevated senescence levels in HNSCC, alongside a novel subtyping based on senescence-associated long noncoding RNAs, highlight significant variations in the tumor microenvironment and treatment responses across different subtypes. We used a set of eight machine learning algorithmsgradient boosting, gradient boosting with cross-validation, gradient boosting machines, linear discriminant analysis, linear discriminant analysis with cross-validation, random forest, support vector machine, and support vector machine with cross-validationto identify the significant ALMS1-IT1/miR-7c-5p/HMGA2 regulatory axis. Single-cell analysis of dysregulated expression within the ALMS1-IT1/miR-7c-5p/HMGA2 axis predominantly highlighted aberrant interactions between immune cells and epithelial cells. Drug sensitivity evaluations suggested that inhibitors targeting ALMS1-IT1, such as sulforaphane and cloxacillin, alongside HMGA2 inhibitors such as ixabepilone, provide innovative, personalized, and combined targeted therapeutic strategies for patients with HNSCC.

24 Mar 2025·Current Drug Safety

Clinical Manifestations of Neuropathic Pain and the Deleterious Effects of Chemotherapeutic Agents

Article

Author: Chakraborty, Manodeep ; Ghosh, Moumita ; Bhattacharjee, Ananya ; Bhuyan, Nihar Ranjan

Abstract::

Neuropathic pain is a type of pain resulting from damage or dysfunction of the nervous system. Chemotherapy-induced peripheral neurotoxicity (CIPN) is a serious complication of cancer treatment, often occurring in a dose-dependent manner. CIPN is a sensory neuropathic syndrome characterized by motor and autonomic alterations of varying intensity and duration. The lack of effective treatment options for CIPN makes it a significant clinical challenge. A variety of chemotherapeutic agents can contribute to the development of CIPN, including vinca alkaloids, platinum-based antineoplastic agents, epothilones (ixabepilone), proteasome inhibitors (bortezomib), taxanes, and immunomodulatory drugs (thalidomide), along with the genetic factors. Single nucleotide polymorphisms (SNPs) in genes, such as CEP72 and EPHA, have been linked to increased susceptibility to CIPN. The treatment options for CIPN are limited and often require careful consideration due to potential side effects and patient comorbidities. Pharmacological interventions, such as anticonvulsants, gabapentin, and pregabalin, are commonly used to manage neuropathic pain. Tricyclic antidepressants like amitriptyline and nortriptyline can be effective, but their use may be limited due to side effects. In severe cases, opioids may be considered, but they should be used cautiously due to the risk of addiction and other adverse effects. The lidocaine or capsaicin creams and patches can provide localized pain relief. The non-pharmacological interventions like physical therapy can help improve strength, balance, and mobility. Transcutaneous electrical nerve stimulation and spinal cord stimulation are invasive procedures that may be considered for severe, intractable pain. Complementary therapies and cognitive-behavioural therapy can help patients cope with pain and improve their quality of life.

News (Medical) associated with Ixabepilone

30 May 2023

·www.biospace.com

First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting

Phase 2 study evaluating the utility of a DRP®companion diagnostic for cisplatin supports its abilityto predict drug response in certain breast cancer patients Boston, MA (May 30, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced the results of a prospective Phase 2 clinical study of the Company’s proprietary DRP® technology that will be presented in a poster at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 3, 2023. In the Phase 1/2 study, researchers analyzed the transcriptomic profiles of 37 evaluable metastatic breast cancer (mBC) patients and, based on analysis of biomarkers comprised within a DRP® signature, assigned response likelihood scores (DRP® 0-100) of patient tumors to a targeted, liposomal form of cisplatin (LiPlaCis™). Data from the poster presentation will show that the cisplatin-DRP® identified all four mBC patients who demonstrated a partial response (PR) in the trial as likely responders to the LiPlaCis™ treatment regimen using a DRP80+ score as a cut-off for likely responders. In addition, the cisplatin-DRP® also identified mBC patients demonstrating other efficacy signals, including improved progression-free survival. Based on these data, researchers concluded that the cisplatin-DRP® companion diagnostic can differentiate, in a statistically significant way, clinical responders and non-responders to cisplatin administered as LiPlaCis™. “While our proprietary DRP® companion diagnostics have been extensively validated in numerous retrospective analyses across multiple forms of cancer and many drug types, these data represent the first prospective clinical study showing that our technology can predict actual patient responses ahead of potential treatment,” said James G. Cullem, Chief Executive Officer of Allarity Therapeutics. “The ability to differentiate likely responders to a specific drug regimen prior to treatment has the potential to provide improved patient benefits and potential clinical trial efficiencies, and we are excited that these data will be shared with our colleagues at this year’s ASCO meeting.” Using a proprietary systems biology algorithm, Allarity’s DRP® technology analyzes transcriptomic differences between cell lines that are sensitive and resistant to provide a biomarker signature of drug response and resistance. The DRP® platform further refines the predictive signature through a clinical relevance filter (created from more than 3,000 actual tumor biopsy samples from a broad range of cancer drug clinical trials) to eliminate unnecessary biomarkers. By remaining agnostic to what influences tumor response or resistance to a drug, DRP® enables the identification of unknown biomarkers crucial to drug response or resistance. Allarity conducted the study in collaboration with investigators at hospitals in Denmark and its CRO Smerud Medical Research International AS. The LiPlaCis™ program is currently licensed to CHOSA Oncology AB for further clinical development. The poster presentation details are as follows: Poster Title: “Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer.” Authors: Nielsen, D., Jakobsen, E,H., Langkjer, S.T., Danoe, H., Balslev, E., Knoop, A., … Lassen, U.N. Abstract Number: 3130 Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Date and Time: 6/3/2023, 8:00 AM-11:00 AM local time About Allarity Therapeutics Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP® platform. The Company has a mature portfolio of three drug candidates: stenoparib, a PARP inhibitor in Phase 2 development for ovarian cancer, and in Phase 1 development for advanced solid tumors in a combination treatment with dovitinib, a pan-tyrosine kinase inhibitor (pan-TKI) that has previously been developed through Phase 3 in renal cancer; and IXEMPRA® (Ixabepilone), a microtubule inhibitor approved in the U.S. and marketed by R-PHARM U.S. for the treatment of second-line metastatic breast cancer, currently in Phase 2 development in Europe for the same indication. Additionally, the Company has rights in two secondary assets: 2X-111, a liposomal formulation of doxorubicin for metastatic breast cancer and/or glioblastoma multiforme (GBM), which is the subject of discussions for a restructured out-license to Smerud Medical Research International AS; and LiPlaCis®, a liposomal formulation of cisplatin and its accompanying DRP®, being developed via a partnership with CHOSA Oncology AB for late-stage metastatic breast cancer. The Company is headquartered in the United States and maintains an R&D facility in Hoersholm, Denmark. For more information, please visit the Company’s website at . About the Drug Response Predictor – DRP® Companion Diagnostic Allarity uses its drug-specific DRP® to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high DRP® score, the therapeutic response rate can be significantly increased. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines combined with clinical tumor biology filters and prior clinical trial outcomes. DRP® is based on messenger RNA from patient biopsies. The DRP® platform has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 37 out of 47 clinical studies that were examined (both retrospective and prospective), including ongoing, prospective Phase 2 trials of Stenoparib and IXEMPRA®. The DRP® platform, which can be used in all cancer types and is patented for more than 70 anti-cancer drugs, has been extensively published in peer-reviewed literature. Follow Allarity on Social Media LinkedIn: Twitter: Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide Allarity’s current expectations or forecasts of future events. The words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements related to the expected availability of capital to fund its anticipated clinical trials, statements related to advancing dovitinib in combination with stenoparib or another therapeutic candidate or other approved drug, any statements related to ongoing clinical trials for stenoparib as a monotherapy or in combination with another therapeutic candidate for the treatment of advanced ovarian cancer, or ongoing clinical trials (in Europe) for IXEMPRA® for the treatment of metastatic breast cancer, statements relating to the effectiveness of the Company’s DRP® companion diagnostics platform in predicting whether a particular patient is likely to respond to a specific drug, and statements related to the Company’s ability to regain compliance with the Nasdaq Listing Rule. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive reviews of the data, and as more patient data become available, the risk that results of a clinical study are subject to interpretation and additional analyses may be needed and/or may contradict such results, the receipt of regulatory approval for dovitinib or any of our other therapeutic candidates or, if approved, the successful commercialization of such products, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our therapeutic candidates, and the risk that the current COVID-19 pandemic will impact the Company’s current and future clinical trials and the timing of the Company’s preclinical studies and other operations. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our Form 10-K annual report on the Securities and Exchange Commission, available at the Securities and Exchange Commission’s website at , and as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. ### U.S. Media Contact: Mike Beyer Sam Brown, Inc. +1 (312) 961-2502 mikebeyer@sambrown.com EU Media Contact: Thomas Pedersen Carrotize PR & Communications +45 6062 9390 tsp@carrotize.com Attachment Allarity - Press Release ASCO presentation

Phase 2ASCOPhase 3Clinical ResultPhase 1

27 Apr 2023

·www.biospace.com

Allarity Therapeutics Accelerates Trial Enrollment To Bring FDA-Approved Breast Cancer Treatment To European Market - Interim Results Could Be Released In Second Half Of 2023

CAMBRIDGE, MA / ACCESSWIRE / April 27, 2023 / Recently, Allarity Therapeutics, Inc. (NASDAQ:ALLR) announced plans to speed up its Phase 2 clinical trial for IXEMPRA®, the clinical-stage pharma company's metastatic breast cancer treatment. Already approved by the Food and Drug Administration (FDA) for patients in the United States, the company is sponsoring this current trial as part of its work to get IXEMPRA® and IXEMPRA-DRP® the companion diagnostic approved as a treatment in Europe. With the accelerated recruitment of patients, Allarity aims to release interim data from the trial in the second half of 2023. The Phase 2 Trial Combines IXEMPRA® With Allarity's Precision Diagnostic Technology Originally developed by Bristol Myers Squibb, IXEMPRA is a small molecule targeted inhibitor of microtubules, the structures that help form the cancer cell's cytoskeleton and regulate cell growth. IXEMPRA® attaches to these microtubules to block the process of dividing and multiplying, ultimately causing the cancer cell to die. As such, it's meant to both kill existing cancer cells and slow the growth of new ones. It was already approved by the FDA for the U.S. market in 2007, where it is marketed by its current owner R-PHARM U.S., LLC, thanks to its ability to increase progression-free survival rates and overall response rates in patients with metastatic breast cancer. Allarity owns exclusive development rights for the drug in Europe, where it is not currently approved. What really sets the Phase 2 trial apart from others, however, is Allarity's patented Drug Response Predictor (DRP®) platform, which the company has used to develop a companion diagnostic to help identify which patients are most likely to benefit from IXEMPRA®, Allarity owns exclusive development rights for the drug in Europe. This is key because as promising as any new cancer treatment may be, the reality is that many patients may not respond or at least not respond as strongly as they would to a different treatment. Most cancer drugs approved by the FDA have a response rate of 40% or less, meaning fewer than half of patients will see a significant reduction in tumor size. The good news is that cancer researchers are identifying more and more biomarkers that can predict whether or not an individual patient's cancer will respond to a particular drug. That includes biomarkers that indicate if a cancer is especially resistant to a drug and biomarkers that suggest if it might be especially vulnerable to it. However, there's no single gene or biomarker that definitively proves a drug will or will not work. Instead, dozens if not hundreds of genes and biomarkers are at play and a single patient can often have a mix of both resistant and susceptible biomarkers. That cancer complexity is why Allarity developed the DRP® platform. Using drug-specific DRP® companion diagnostics, doctors will be able to not only rule out drugs that a patient is unlikely to respond to but hone in on the course of treatment with the best chance of producing the best results. This can save thousands of dollars for patients by avoiding ineffective treatments and improve their odds of remission by getting them on the right treatment for their particular cancer as soon as possible. Already deployed in over 47 cancer trials, the DRP® platform technology has yielded a high success rate with more than 80% predictive accuracy thanks to its systems biology analysis approach. Starting with analysis of messenger RNA taken from cancer cell lines treated with a given drug, the DRP® platform generates an initial gene expression signature that predicts whether a tumor will (or will not) respond to the drug. The DRP® platform then refines this predictive signature through a proprietary clinical relevance filter comprising drug response/resistance data from thousands of biopsy samples from actual patients in prior oncology clinical trials. The result is a unique DRP® signature (or companion diagnostic) based on 50 to 400 biomarkers. That signature can then be compared to messenger RNA data from a specific patient's tumor to generate a DRP® score, a measure of how likely the patient is to respond to that drug. In the IXEMPRA® trial, for example, Allarity is enrolling patients with at least a 33% DRP® score for the breast cancer therapy. In addition to measuring the efficacy of the therapy, the trial will also be used to further validate the predictive accuracy of the DRP® companion diagnostic by comparing response rates to patients' initial DRP® scores. As the company implements the amended trial protocol to speed up enrollment, by having lowered the IXEMPRA-DRP® companion diagnostic cut-off score, for enrollment, from 67% to 33%, and by expanding its CRO partnerships, meaning more sites will participate in the trial, it's working to advance towards hopeful approval for the European market, where Allarity holds exclusive option rights to the drug. Featured photo by National Cancer Institute on Unsplash Contact: US investor contact: Thomas Jensen, investorrelations@allarity.com +4522 930837 EU investor contact: Thomas Pedersen tsp@carrotize.com +45 60629390 SOURCE: Allarity Therapeutics, Inc. View source version on accesswire.com:

Phase 2

20 Apr 2023

·www.biospace.com

Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering

Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering BOSTON, MA (April 19, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced the pricing of its “reasonable best efforts” public offering of 2,869,330 shares of common stock, 7,130,670 pre-funded warrants, and 10,000,000 common warrants to purchase 10,000,000 shares of common stock at an effective combined price of $0.75 per share and common warrant for aggregate gross proceeds of approximately $7.5 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $0.85 per share, will be exercisable immediately and will expire five years from the initial exercise date. The closing of the offering is expected to occur on or about April 21, 2023, subject to the satisfaction of customary closing conditions. The Company intends to use a portion of the net proceeds of this offering to pay account payables and accrued liabilities outstanding, to payoff certain outstanding promissory notes, to redeem a portion of its Series A Convertible Preferred Stock and for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering. The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-270514) previously filed with the Securities and Exchange Commission (SEC) which became effective on April 18, 2023. The offering is being made only by means of a prospectus forming part of the effective registration statement. Copies of the preliminary prospectus and, when available, copies of the final prospectus, relating to the offering may be obtained on the SEC’s website located at Electronic copies of the final prospectus relating to the offering may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Allarity Therapeutics Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP® platform. The Company has a mature portfolio of three drug candidates: stenoparib, a PARP inhibitor in Phase 2 development for ovarian cancer; dovitinib, a pan-tyrosine kinase inhibitor previously developed through Phase 3 in renal cancer; and IXEMPRA® (Ixabepilone), a microtubule inhibitor approved in the U.S. and marketed by R-PHARM U.S. for the treatment of second-line metastatic breast cancer, and is currently in Phase 2 development in Europe for the same indication. Additionally, the Company has rights in two secondary assets: 2X-111, a liposomal formulation of doxorubicin for metastatic breast cancer and/or glioblastoma multiforme (GBM), which is the subject of discussions for a restructured out-license to Smerud Medical Research International AS; and LiPlaCis®, a liposomal formulation of cisplatin and its accompanying DRP®, being developed via a partnership with Chosa Oncology AB for late-stage metastatic breast cancer. The Company is headquartered in the United States and maintains an R&D facility in Hoersholm, Denmark. For more information, please visit the Company’s website at . About the Drug Response Predictor – DRP ® Companion Diagnostic Allarity uses its drug specific DRP to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high DRP score, the therapeutic response rate can be significantly increased. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA from patient biopsies. The DRP platform has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 37 out of 47 clinical studies that were examined (both retrospective and prospective), including ongoing, prospective Phase 2 trials of Stenoparib and IXEMPRA®. The DRP platform, which can be used in all cancer types and is patented for more than 70 anti-cancer drugs, has been extensively published in peer reviewed literature. Follow Allarity on Social Media Facebook: LinkedIn: Twitter: Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide Allarity’s current expectations or forecasts of future events. The words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements related to the Company’s ability to regain compliance with the Nasdaq Listing Rule, use of proceeds from the offering, that the closing of offering will occur or will occur on the anticipated closing date, ability to raise capital, statements related to the expected availability capital to fund its anticipated clinical trials, statements related to advancing dovitinib in combination with another therapeutic candidate or other approved drug, any statements related to ongoing clinical trials for stenoparib as a monotherapy or in combination with another therapeutic candidate for the treatment of advanced ovarian cancer, or ongoing clinical trials (in Europe) for IXEMPRA® for the treatment of metastatic breast cancer, and statements relating to the effectiveness of the Company’s DRP® companion diagnostics platform in predicting whether a particular patient is likely to respond to a specific drug. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive reviews of the data, and as more patient data become available, the risk that results of a clinical study are subject to interpretation and additional analyses may be needed and/or may contradict such results, the receipt of regulatory approval for dovitinib or any of our other therapeutic candidates or, if approved, the successful commercialization of such products, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our therapeutic candidates, and the risk that the current COVID-19 pandemic will impact the Company’s current and future clinical trials and the timing of the Company’s preclinical studies and other operations. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our Form S-1 registration statement on the Securities and Exchange Commission, available at the Securities and Exchange Commission’s website at and as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. ### Company Contact: Thomas Jensen Senior V.P. of Investor Relations investorrelations@allarity.com U.S. Media Contact: Mike Beyer Sam Brown, Inc. +1 (312) 961-2502 mikebeyer@sambrown.com EU Media Contact: Thomas Pedersen Carrotize PR & Communications +45 6062 9390 tsp@carrotize.com Attachment Allarity Therapeutics Press Release - Public Offering Pricing Announcement

Phase 2Drug ApprovalClinical Result

100 Deals associated with Ixabepilone

External Link

KEGG	Wiki	ATC	Drug Bank
D04645	Ixabepilone	L01DC04	DB04845

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Breast Cancer	Switzerland	Recordati AG	27 Feb 2009
Locally advanced breast cancer	United States	R-Pharm US LLC	16 Oct 2007

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Endometrial Carcinoma	Phase 3	United States	R-Pharm JSC	01 Aug 2009
Advanced Endometrial Carcinoma	Phase 3	Argentina	R-Pharm JSC	01 Aug 2009
Advanced Endometrial Carcinoma	Phase 3	Australia	R-Pharm JSC	01 Aug 2009
Advanced Endometrial Carcinoma	Phase 3	Belgium	R-Pharm JSC	01 Aug 2009
Advanced Endometrial Carcinoma	Phase 3	Brazil	R-Pharm JSC	01 Aug 2009
Advanced Endometrial Carcinoma	Phase 3	Canada	R-Pharm JSC	01 Aug 2009
Advanced Endometrial Carcinoma	Phase 3	Czechia	R-Pharm JSC	01 Aug 2009
Advanced Endometrial Carcinoma	Phase 3	Denmark	R-Pharm JSC	01 Aug 2009
Advanced Endometrial Carcinoma	Phase 3	France	R-Pharm JSC	01 Aug 2009
Advanced Endometrial Carcinoma	Phase 3	Greece	R-Pharm JSC	01 Aug 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03093155 (NCT03093155, Pubmed)	Phase 2	Platinum-Resistant Primary Peritoneal Carcinoma paclitaxel-refractory \| paclitaxel-resistant \| taxane-sensitive	-	Ixabepilone 20 mg/m2	cbczysqjkx(jrydmdkvbu) = bvashnknrj nvrsrghqhi (etienjjcdk ) View more	Positive	20 Jun 2024
				Ixabepilone 20 mg/m2 + Bevacizumab 10 mg/kg	cbczysqjkx(jrydmdkvbu) = motsquyzni nvrsrghqhi (etienjjcdk ) View more
NCT03093155 (RP2 \| NCT03093155, CTgov)	Phase 2	Platinum-Resistant Primary Peritoneal Carcinoma \| Ovarian Epithelial Carcinoma \| Fallopian Tube Carcinoma	78	Ixabepilone (Ixabepilone)	dnsxihwtmy(uwxeysiajk) = ekoqkcizna glsxymriec (oqzhervztp, sbvpeszolb - fcrljwxygy) View more	-	14 May 2024
				Ixabepilone+Bevacizumab (Ixabepilone + Bevacizumab)	dnsxihwtmy(uwxeysiajk) = irqeputpyi glsxymriec (oqzhervztp, lbsdkoqlct - xfrfaujytz) View more
NCT03093155 (RP2, Pubmed \| Br J Cancer)	Phase 2	Platinum-Resistant Primary Peritoneal Carcinoma class III-ß-tubulin (TUBB3)	76	Ixabepilone + Bevacizumab	xtgrkfkjae(qlhpiqpgxd) = yudzlmacrg yjtkggclun (otldcxaobc, 0.19 - 0.55) View more	Positive	01 Jun 2022
				Ixabepilone	xtgrkfkjae(qlhpiqpgxd) = dckqgwhpau yjtkggclun (otldcxaobc ) View more
NCT01446016 (CAT, CTgov)	Phase 2	Metastatic breast cancer \| Advanced breast cancer	38	Abraxane+Ixabepilone+Paclitaxel+Docetaxel	fubjkfriye = zomhxivmao luywwelvgh (fquzfbngdd, gsdwwmvdcc - scytixzgyo) View more	-	01 Feb 2022
NCT00630032 (UNICANCER-PACS08 \| TavIx, CTgov)	Phase 3	Triple Negative Breast Cancer	762	cyclophosphamide+Docetaxel+epirubicin hydrochloride+fluorouracil (Docetaxel)	arijumnpzo = ioqvfhwmtj gxsjrepjhy (qxmleuftev, snwgyxzdic - lidzjwvvvc) View more	-	16 Mar 2021
				ixabepilone+cyclophosphamide+epirubicin hydrochloride+fluorouracil (Ixabepilone)	arijumnpzo = eyycfafkgc gxsjrepjhy (qxmleuftev, vzcasgvowq - lznbwcabfx) View more
ASCO2020	Not Applicable	Metastatic breast cancer	91	Ixabepilone	behgvdsavj(pmxuytljdq) = Grade 3 or higher anemia was present in 10% of the patients oggwdgnwpx (fndfswjddq ) View more	Positive	25 May 2020
NCT00630032 (UNICANCER-PACS08, Pubmed) Manual	Phase 3	Breast Cancer Adjuvant	762	5-FU+epirubicin+cyclophosphamide+ixabepilone	qqzmastwnc(ifehkzajif) = puqjnmfajz mlwbyheqqj (egyywubwuf ) View more	Similar	01 Nov 2018
				5-FU+epirubicin+cyclophosphamide+docetaxel	qqzmastwnc(ifehkzajif) = nayybndxcl mlwbyheqqj (egyywubwuf ) View more
NCT00785291 (CALGB 40502/NCCTG N063H (Alliance), SABCS2018)	Phase 3	Metastatic breast cancer First line hormone receptor positive \| triple negative	799	Paclitaxel	jrdaxtgjwc(sjnirkbecr) = exvgzifckc yvkfpgbrua (omaekkbqic ) View more	Negative	15 Feb 2018
				Nanoparticle albumin bound nab-Paclitaxel	jrdaxtgjwc(sjnirkbecr) = lfkdlbsvko yvkfpgbrua (omaekkbqic ) View more
NCT00923130 (Pubmed) Manual	Phase 2	Advanced Renal Cell Carcinoma Second line	30	Bevacizumab+Ixabepilone	igxwgojjuu(ntroiepxie) = udlgthvvoc qwhrfzmvbe (mhesdnuxmq ) View more	Negative	01 Aug 2017
NCT00789581 (TITAN, Pubmed \| Breast Cancer Res Treat)	Phase 3	Triple Negative Breast Cancer Adjuvant	614	AC/ixabepilone	skbzhncwrk(ugtjwijftz) = Peripheral neuropathy was the most common grade 3/4 event. Dose reductions and treatment discontinuations occurred more frequently during paclitaxel treatment. ertpbiksjl (zybucrxdnb )	Positive	01 Aug 2017
				AC/paclitaxel

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis